Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
International Society for Gastrointestinal Hereditary Tumours |
RCV000076652 | SCV000107687 | pathogenic | Lynch syndrome I | 2014-10-10 | reviewed by expert panel | research | Multifactorial likelihood analysis posterior probability >0.99 |
Invitae | RCV000811653 | SCV000951929 | uncertain significance | Hereditary nonpolyposis colorectal neoplasms | 2018-09-13 | criteria provided, single submitter | clinical testing | This sequence change replaces valine with aspartic acid at codon 200 of the MSH2 protein (p.Val200Asp). The valine residue is moderately conserved and there is a large physicochemical difference between valine and aspartic acid. This variant is not present in population databases (ExAC no frequency). This variant has been reported in individuals in the Leiden Open-source Variation Database (PMID: 21520333). ClinVar contains an entry for this variant (Variation ID: 91148). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |